Skip to main content
Industry News
AbbVie reportedly drops global patent rights for HIV drug

AbbVie will reportedly give up global patent rights for its HIV drug Kaletra, which is being evaluated in several clinical trials as treatment for severe COVID-19, to address rising demand for experimental coronavirus drugs. The move will allow countries to buy Kaletra generics if the drug is found to be an effective COVID-19 treatment or if a shortage occurs.

Full Story: